With Verkazia, you can now treat vernal keratoconjunctivitis (VKC) year-round1

The first and only topical immunomodulator FDA-approved for the treatment of VKC in children and adults1

Image
Year round control of vernal keratoconjunctivitis with Verkazia
Image
Year round control of vernal keratoconjunctivitis with Verkazia
1200ms

In children and adults with VKC, Verkazia delivered:

Image
Verkazia helps itchy eyes

Reduction in itching and keratitis scores as early as month 11

See efficacy
Image
Verkazia treats VKC symptoms

Additional reductions in photophobia, mucous discharge, and tearing observed over 4 months in the pivotal multicenter trial2

Explore results
Image
Verkazia is safe to take over a long period

Established 12-month safety profile with low rates of mild-to-moderate adverse events1,3

See the data